dndn announcement only a week away, page-3

Some information on DNDN:

http://finance.yahoo.com/q?s=dndn

Basically they are expecting news on FDA approval for their therapeutic vaccine Provenge on the 1st of May.

If approved, it may improve investor sentiment to the wider therapeutic vaccine sector of which VHL is a part. VHL owns a platform technology base, they are also about to release Phase II trial results for VIR-201 which if positive may excite the market.

Still a risky stock, weak balance sheet and uncertain future however approval for a potential blockbuster in the US may improve sentiment towards other vaccine developers. PRR may also benefit although it has a higher cap than VHL.

I hold... looking forward to the Phase II results but DNDN approval may have an impact on investor awareness to VHL... but then again it may not.